ALBANY, N.Y., March 19, 2026 (GLOBE NEWSWIRE) -- A Curia, uma organização líder em pesquisa, desenvolvimento e fabricação por contrato (CDMO), anunciou hoje o progresso na expansão da sua unidade [...] Read more »
Curia Expands Glasgow Manufacturing Capacity and Enhances Cell Line Development Platform
ALBANY, N.Y., March 19, 2026 (GLOBE NEWSWIRE) -- Curia, a leading contract research, development and manufacturing organization (CDMO), today announced progress on the expansion at its Glasgow, UK sterile drug product facility [...] Read more »
Kyowa Kirin Recupera Controle do Programa de Desenvolvimento e Comercialização do Rocatinlimab, Demonstrando Forte Compromisso para Abordar a Alta Necessidade Médica Não Atendida na Dermatite Atópica
- A Kyowa Kirin afirma o compromisso de desenvolver o rocatinlimab como um ativo diferenciado de mudança de vida com potencial de mercado significativo.
- Read more »
Kyowa Kirin reprend le contrôle du programme de développement et de commercialisation du rocatinlimab, manifestant ainsi son profond engagement visant à répondre aux besoins médicaux non satisfaits dans le domaine de la dermatite atopique
- Kyowa Kirin réaffirme sa volonté de développer le rocatinlimab comme un traitement innovant capable d’améliorer significativement la vie des patients, tout en [...] Read more »
Kyowa Kirin erlangt Kontrolle über Entwicklungs- und Kommerzialisierungsprogramm für Rocatinlimab wieder, zeigt starkes Engagement im Bereich des ungedeckten medizinischen Bedarfs bei atopischer Dermatitis
- Kyowa Kirin bestätigt Engagement für die Entwicklung von Rocatinlimab als lebensveränderndes differenziertes Feld mit bedeutendem Marktpotenzial.
- Read more »
Kyowa Kirin to Regain Control of Rocatinlimab Development and Commercialization Program, Demonstrating Strong Commitment to Address High Unmet Medical Need in Atopic Dermatitis
- Kyowa Kirin affirms commitment to developing rocatinlimab as a life–changing differentiated asset with significant market potential.
- Rocatinlimab’s novel approach as an investigational [...] Read more »
Countdown for a Cure Partners with Dr. Taz Bhatia M.D. and hol+ to Advance Mitochondrial Research and Awareness
ATLANTA, Jan. 23, 2026 (GLOBE NEWSWIRE) — Dr. Taz Bhatia M.D., a nationally recognized integrative medicine physician, author, and founder of hol+, has partnered with nonprofit Countdown for a Cure (CFAC) to help advance [...] Read more »
Attindas Hygiene Partners Amplia Parceira na Europa com Importante Aquisição
RALEIGH, N.C., Jan. 09, 2026 (GLOBE NEWSWIRE) — Attindas Hygiene Partners dá um passo importante para sua estratégia de crescimento hoje com a aquisição da Societá Italiana [...] Read more »
Attindas Hygiene Partners renforce sa position en Europe grâce à une acquisition stratégique
RALEIGH, Caroline du Nord, 10 janv. 2026 (GLOBE NEWSWIRE) — Attindas Hygiene Partners exécute aujourd’hui une étape majeure dans sa stratégie de croissance avec l’acquisition de Società [...] Read more »
Attindas Hygiene Partners baut mit bedeutender Akquisition seine Position in Europa aus
RALEIGH, North Carolina, Jan. 10, 2026 (GLOBE NEWSWIRE) — Die Wachstumsstrategie von Attindas Hygiene Partners hat heute mit der Übernahme von Società Italiana Lavorazione Cellulosa (SILC S.p.A.) einen wichtigen [...] Read more »
Attindas Hygiene Partners Expands European Position with Key Acquisition
RALEIGH, N.C., Jan. 09, 2026 (GLOBE NEWSWIRE) — Attindas Hygiene Partners’ growth strategy realized an important step forward today with its acquisition of Societá Italiana Lavorazione Cellulosa (SILC [...] Read more »
Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks
- REC–4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12)
- After 12 weeks [...] Read more »
Sabin Vaccine Institute’s Investigational Marburg Vaccine Delivered to Ethiopia for Outbreak Response
WASHINGTON, Dec. 04, 2025 (GLOBE NEWSWIRE) — The Sabin Vaccine Institute (Sabin) has sent more than 640 doses of its investigational cAd3–Marburg Vaccine to Ethiopia to support the [...] Read more »
Minovia Therapeutics Mitochondrial Augmentation Technology to be Featured in Presentation and Workshop at the 67th ASH Annual Meeting and Exposition
HAIFA, Israel, Nov. 20, 2025 (GLOBE NEWSWIRE) — Minovia Therapeutics Ltd. (“Minovia” or the “Company”), a clinical–stage biotechnology company developing novel therapies to treat [...] Read more »
شركة Profound Medical توقع اتفاقية توزيع حصرية لمنتجات TULSA-PRO®وSonalleve® مع شركة Al Faisaliah Medical Systems في المملكة العربية السعودية
الاتفاقية تفتح المجال أمام علاجات [...] Read more »